Michael Sullivan-Mee1, My Tho Karin Tran2, Denise Pensyl3, Grace Tsan3, Suchitra Katiyar3. 1. New Mexico VA HCS, Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico. Electronic address: Michael.Sullivan-Mee@va.gov. 2. Department of Ophthalmology, University of New Mexico Hospitals, Albuquerque, New Mexico. 3. New Mexico VA HCS, Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico.
Abstract
PURPOSE: To investigate the clinical characteristics of 10-2 visual field defects in subjects with a diagnosis of glaucoma or glaucoma suspicion. DESIGN: Prospective, observational cohort study. METHODS: From participants enrolled in an ongoing glaucoma research study at our institution, we identified 354 eyes in 180 subjects (97 with primary open-angle glaucoma, 83 with glaucoma suspicion) who had 2 or more reliable 24-2 and 10-2 visual field tests and good-quality spectral-domain optical coherence tomography (SDOCT) scans. Eyes with macular pathology, significant cataract, or nonglaucomatous vision loss were excluded. We applied previously published cluster criteria to define 10-2 visual field loss, and then calculated prevalence, location, severity, and pattern of 10-2 visual field loss as well as its relationships with various functional and structural parameters. RESULTS: Repeatable 10-2 visual field defects were present in 89 of 180 subjects (49%) and usually exhibited an arcuate or nasal pattern. In eyes with no, mild, moderate, and advanced 24-2 visual field loss, 15 of 236 (6%), 49 of 67 (73%), 25 of 26 (96%), and 25 of 25 (100%) had 10-2 visual field defects, respectively. Of the 114 eyes with 10-2 visual field loss, 93 (82%) demonstrated abnormal points within the central 10 degrees of the 24-2 visual field test. Mean defect on the 10-2 and 24-2 tests was highly correlated (r(2) = 0.72). CONCLUSIONS: Although central VF loss appears to be common in glaucoma and may have an important role in glaucoma management, additional study is warranted to more definitively determine the optimal methods to detect presence, severity, and functional impact of central glaucomatous visual field loss. Published by Elsevier Inc.
PURPOSE: To investigate the clinical characteristics of 10-2 visual field defects in subjects with a diagnosis of glaucoma or glaucoma suspicion. DESIGN: Prospective, observational cohort study. METHODS: From participants enrolled in an ongoing glaucoma research study at our institution, we identified 354 eyes in 180 subjects (97 with primary open-angle glaucoma, 83 with glaucoma suspicion) who had 2 or more reliable 24-2 and 10-2 visual field tests and good-quality spectral-domain optical coherence tomography (SDOCT) scans. Eyes with macular pathology, significant cataract, or nonglaucomatous vision loss were excluded. We applied previously published cluster criteria to define 10-2 visual field loss, and then calculated prevalence, location, severity, and pattern of 10-2 visual field loss as well as its relationships with various functional and structural parameters. RESULTS: Repeatable 10-2 visual field defects were present in 89 of 180 subjects (49%) and usually exhibited an arcuate or nasal pattern. In eyes with no, mild, moderate, and advanced 24-2 visual field loss, 15 of 236 (6%), 49 of 67 (73%), 25 of 26 (96%), and 25 of 25 (100%) had 10-2 visual field defects, respectively. Of the 114 eyes with 10-2 visual field loss, 93 (82%) demonstrated abnormal points within the central 10 degrees of the 24-2 visual field test. Mean defect on the 10-2 and 24-2 tests was highly correlated (r(2) = 0.72). CONCLUSIONS: Although central VF loss appears to be common in glaucoma and may have an important role in glaucoma management, additional study is warranted to more definitively determine the optimal methods to detect presence, severity, and functional impact of central glaucomatous visual field loss. Published by Elsevier Inc.
Authors: Carlos Gustavo De Moraes; Ashley Sun; Ravivarn Jarukasetphon; Rashmi Rajshekhar; Lynn Shi; Dana M Blumberg; Jeffrey M Liebmann; Robert Ritch; Donald C Hood Journal: JAMA Ophthalmol Date: 2019-02-01 Impact factor: 7.389
Authors: Aakriti G Shukla; Portia E Sirinek; C Gustavo De Moraes; Dana M Blumberg; George A Cioffi; Alon Skaat; Christopher A Girkin; Robert N Weinreb; Linda M Zangwill; Donald C Hood; Jeffrey M Liebmann Journal: J Glaucoma Date: 2020-06 Impact factor: 2.503
Authors: C Gustavo De Moraes; Donald C Hood; Abinaya Thenappan; Christopher A Girkin; Felipe A Medeiros; Robert N Weinreb; Linda M Zangwill; Jeffrey M Liebmann Journal: Ophthalmology Date: 2017-05-24 Impact factor: 12.079
Authors: Donald C Hood; Abinaya A Thenappan; Emmanouil Tsamis; Jeffrey M Liebmann; C Gustavo De Moraes Journal: Am J Ophthalmol Date: 2020-08-07 Impact factor: 5.258
Authors: Eren Ekici; Sasan Moghimi; Huiyuan Hou; James Proudfoot; Linda M Zangwill; Jiun L Do; Won Hyuk Oh; Alireza Kamalipour; Jeffrey M Liebmann; Carlos Gustavo De Moraes; Christopher A Girkin; Nevin El-Nimri; Robert N Weinreb Journal: Am J Ophthalmol Date: 2020-10-29 Impact factor: 5.258